000046558 000__ 01079cam\a22003855i\4500
000046558 001__ 46558
000046558 003__ SzGeWIPO
000046558 005__ 20240708150245.0
000046558 006__ m\\\\eo\\d\\\\\\\\
000046558 007__ cr bn |||m|||a
000046558 008__ 221017s2021\\\\nyu\\\\\o\\\\\000\0\eng\d
000046558 035__ $$a(OCoLC)1348117718
000046558 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000046558 041__ $$aeng
000046558 24500 $$aRegeneron Pharmaceuticals Inc v Kymab Ltd (SC).
000046558 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2021
000046558 300__ $$a1 online resource
000046558 336__ $$atext$$2rdacontent
000046558 337__ $$acomputer$$2rdamedia
000046558 338__ $$aonline resource$$bcr$$2rdacarrier
000046558 4901_ $$aInternational Review of Intellectual Property Law & Competition Law,$$x0018-9855 ;$$vVolume 52, Issue 3
000046558 542__ $$fhttps://1.next.westlaw.com/Copyright
000046558 588__ $$aCrossref
000046558 590__ $$aPublished online: 2021
000046558 650_0 $$aIntellectual property.
000046558 650_4 $$aPatents$$zEurope
000046558 650_0 $$aHealth.
000046558 650_4 $$aPharmaceuticals
000046558 7731_ $$tInternational Review of Intellectual Property Law & Competition Law
000046558 7731_ $$wIIC
000046558 830_0 $$aInternational Review of Intellectual Property Law & Competition Law ;$$vIIC 2021, 52(3), 345-346
000046558 85641 $$uhttps://www.westlaw.com/Document/I03730BB09E4711EB80EEB106AF76DF66/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000046558 904__ $$aJournal article
000046558 980__ $$aIIC